CVRx Welcomes New Board Members to Strengthen Leadership
CVRx, Inc. (NASDAQ: CVRX), a leading medical device company, has announced some exciting updates to its Board of Directors. Effective immediately, Kevin Ballinger and Mitch Hill will be joining the board. These new appointments are designed to enhance the leadership team as the company continues its dedication to innovative healthcare solutions. With these changes, the Board now consists of seven committed members.
New Appointments Bring a Wealth of Experience
Kevin Hykes, the President and CEO of CVRx, shared his enthusiasm about the new board members. He remarked, "We are excited to welcome Kevin and Mitch to our Board of Directors. Their extensive backgrounds in the medical device industry, along with their proven records of driving growth and innovation, will be crucial as we work to increase the adoption of our Barostim therapy." Hykes emphasized that Kevin’s deep expertise in interventional cardiology and Mitch’s financial acumen in high-growth healthcare environments align well with the company’s strategic objectives.
Kevin Ballinger’s Background and Contributions
Kevin Ballinger comes to the CVRx board with an impressive background, boasting over 25 years of experience in the medical device sector. Most recently, he was the CEO of Aldevron, LLC, where he oversaw its growth and successful acquisition by Danaher Corporation. His previous experience at Boston Scientific Corporation further honed his leadership abilities, where he held various positions, including Executive Vice President and Global President of Interventional Cardiology. Ballinger’s extensive knowledge in product development and strategic planning is expected to significantly advance CVRx’s mission in the cardiovascular field. Additionally, he has served on the boards of Silk Road Medical, Inc. and previously Shockwave Medical, Inc., which adds further value to his role at CVRx.
Mitch Hill's Financial Expertise
Mitch Hill brings over 30 years of diverse financial and operational experience, particularly within the healthcare and technology sectors. He is transitioning from his position as Chief Financial Officer at Inari Medical, Inc., where he played a key role in leading the company through its initial public offering and rapid growth. His previous executive roles at Cameron Health, Inc. and Visiogen Inc., both of which were acquired during his tenure, highlight Hill’s capability to guide companies through transformative phases. His additional experience at Walt Disney Imagineering and Disney Development Co. showcases his versatile leadership skills.
Gratitude for Ali Behbahani’s Service
In addition to the new appointments, the company also announced the departure of Ali Behbahani, who has been a board member since 2013. Hykes expressed gratitude for Behbahani’s invaluable contributions, stating, "On behalf of CVRx and the Board of Directors, I would like to extend our heartfelt thanks to Ali for his unwavering support of the company throughout much of our history. His expertise has been instrumental in the development and commercialization of the Barostim therapy, positively impacting countless patients dealing with heart failure."
About CVRx, Inc.
CVRx is committed to advancing medical technology, particularly through the Barostim™ System, which is recognized as the first FDA-approved device that utilizes neuromodulation to alleviate symptoms of heart failure. This implantable device sends electrical pulses to baroreceptors in the carotid artery, initiating a natural autonomic response that helps restore balance in the nervous system. The Barostim therapy has received the FDA Breakthrough Device designation and is approved for use in the U.S., also earning recognition in Europe for its effectiveness in treating heart failure and resistant hypertension.
Investor and Media Contact Information
If you have any investor-related questions, please reach out to Mark Klausner or Mike Vallie at ICR Westwicke by calling 443-213-0501 or emailing ir@cvrx.com. For media inquiries, contact Laura O’Neill at Finn Partners by calling 402-499-8203 or emailing laura.oneill@finnpartners.com.
Frequently Asked Questions
Who are the new members appointed to CVRx's Board of Directors?
Kevin Ballinger and Mitch Hill have been appointed to CVRx's Board of Directors.
What is the significance of the Barostim therapy?
The Barostim therapy is a groundbreaking treatment for heart failure, utilizing neuromodulation to restore balance in the autonomic nervous system.
How long has Ali Behbahani served on the board of CVRx?
Ali Behbahani has served on the board since 2013 before his recent departure.
What experience does Kevin Ballinger bring to CVRx?
Kevin Ballinger brings over 25 years of extensive experience in the medical device industry and strategic leadership roles.
How can I contact CVRx for investment inquiries?
Investors can contact Mark Klausner or Mike Vallie at ICR Westwicke by calling 443-213-0501 or emailing ir@cvrx.com.
